Free Trial
NASDAQ:TRAW

Traws Pharma (TRAW) Stock Price, News & Analysis

Traws Pharma logo
$1.50 0.00 (0.00%)
As of 10:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Traws Pharma Stock (NASDAQ:TRAW)

Key Stats

Today's Range
$1.47
$1.55
50-Day Range
$1.42
$1.87
52-Week Range
$0.97
$19.44
Volume
14,746 shs
Average Volume
540,690 shs
Market Capitalization
$8.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Traws Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

TRAW MarketRank™: 

Traws Pharma scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Traws Pharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Traws Pharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Traws Pharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Traws Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    3.30% of the float of Traws Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Traws Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Traws Pharma has recently decreased by 33.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Traws Pharma does not currently pay a dividend.

  • Dividend Growth

    Traws Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.30% of the float of Traws Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Traws Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Traws Pharma has recently decreased by 33.88%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Traws Pharma this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Traws Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.60% of the stock of Traws Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.95% of the stock of Traws Pharma is held by institutions.

  • Read more about Traws Pharma's insider trading history.
Receive TRAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter.

TRAW Stock News Headlines

Former CIA Officer Reveals How Gold Saved His Life
This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained to stay alive when systems collapse. In Operation Gold Rush, Jason Hanson reveals how gold and silver saved his life—and how they could protect yours in the next crisis. You’ll learn how to hide gold like a covert operative, secure your 401(k) in physical assets, and prepare for grid failures, economic collapse, or worse.
TRAW - Traws Pharma Inc Sustainability - Morningstar
See More Headlines

TRAW Stock Analysis - Frequently Asked Questions

Traws Pharma's stock was trading at $8.88 on January 1st, 2025. Since then, TRAW stock has decreased by 83.1% and is now trading at $1.50.

Traws Pharma, Inc. (NASDAQ:TRAW) issued its quarterly earnings results on Thursday, May, 15th. The company reported $2.09 EPS for the quarter, topping the consensus estimate of ($8.04) by $10.13. The firm earned $0.06 million during the quarter, compared to the consensus estimate of $0.06 million.

Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Traws Pharma investors own include Clearside Biomedical (CLSD), Evofem Biosciences (EVFM), Palatin Technologies (PTN), Sirius XM (SIRI), Adverum Biotechnologies (ADVM) and Aptinyx (APTX).

Company Calendar

Last Earnings
5/15/2025
Today
8/11/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRAW
Previous Symbol
NASDAQ:TRAW
CIK
1130598
Employees
17
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($32.81)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$166.52 million
Net Margins
-15,245.81%
Pretax Margin
-61,696.04%
Return on Equity
N/A
Return on Assets
-193.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.81
Quick Ratio
1.81

Sales & Book Value

Annual Sales
$230 thousand
Price / Sales
36.26
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($8.66) per share
Price / Book
-0.17

Miscellaneous

Outstanding Shares
5,560,000
Free Float
4,807,000
Market Cap
$8.34 million
Optionable
Optionable
Beta
1.14
10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:TRAW) was last updated on 8/11/2025 by MarketBeat.com Staff
From Our Partners